Monoamine oxidase A inhibition and Parkinson’s disease

Neurodegenerative Disease ManagementVol. 10, No. 6 EditorialMonoamine oxidase A inhibition and Parkinson's diseasePhilippe HuotPhilippe Huot *Author for correspondence: Tel.: +1 514 398 5957; Fax: +1 514 398 2304; E-mail Address: philippe.huot@mcgill.cahttps://orcid.org/0000-0002-5464-8334Neurodegenerative Disease Group, Montreal Neurological Institute, Montreal, QC H3A 2B4, CanadaDepartment of Neurology & Neurosurgery, McGill University, Montreal, QC H3A 2B4, CanadaMovement Disorder Clinic, Division of Neurology, Department of Neuroscience, McGill University Health Centre, Montreal, QC H3A 2B4, CanadaPublished Online:27 Aug 2020https://doi.org/10.2217/nmt-2020-0043AboutSectionsView ArticleView Full TextPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareShare onFacebookTwitterLinkedInReddit View articleKeywords: moclobemidemonoamine oxidase AParkinson's diseaseparkinsonismReferences1. Hornykiewicz O, Kish SJ. Biochemical pathophysiology of Parkinson's disease. Adv. Neurol. 45, 19–34 (1987).Medline, CAS, Google Scholar2. Connolly BS, Lang AE. Pharmacological treatment of Parkinson disease: a review. JAMA 311(16), 1670–1683 (2014).Crossref, Medline, Google Scholar3. Glover V, Sandler M, Owen F, Riley GJ. Dopamine is a monoamine oxidase B substrate in man. Nature 265(5589), 80–81 (1977).Crossref, Medline, CAS, Google Scholar4. Fox SH, Katzenschlager R, Lim SY et al. International Parkinson and Movement Disorder Society evidence-based medicine review: update on treatments for the motor symptoms of Parkinson's disease. Mov. Disord. 33(8), 1248–1266 (2018).Crossref, Medline, CAS, Google Scholar5. Fowler CJ, Benedetti MS. The metabolism of dopamine by both forms of monoamine oxidase in the rat brain and its inhibition by cimoxatone. J. Neurochem. 40(6), 1534–1541 (1983).Crossref, Medline, CAS, Google Scholar6. Colzi A, D'Agostini F, Cesura AM, Borroni E, Da Prada M. Monoamine oxidase-A inhibitors and dopamine metabolism in rat caudatus: evidence that an increased cytosolic level of dopamine displaces reversible monoamine oxidase-A inhibitors in vivo. J. Pharmacol. Exp. Ther. 265(1), 103–111 (1993).Medline, CAS, Google Scholar7. Lakshmana MK, Rao BS, Dhingra NK et al. Role of monoamine oxidase type A and B on the dopamine metabolism in discrete regions of the primate brain. Neurochem. Res. 23(8), 1031–1037 (1998).Crossref, Medline, CAS, Google Scholar8. O'Carroll AM, Fowler CJ, Phillips JP, Tobbia I, Tipton KF. The deamination of dopamine by human brain monoamine oxidase. Specificity for the two enzyme forms in seven brain regions. Naunyn Schmiedebergs Arch. Pharmacol. 322(3), 198–202 (1983).Crossref, Medline, Google Scholar9. Hamadjida A, Nuara SG, Frouni I et al. Monoamine oxidase A inhibition as monotherapy reverses parkinsonism in the MPTP-lesioned marmoset. Naunyn Schmiedebergs Arch. Pharmacol. doi:10.1007/s00210-020-01927-w (2020) (Epub ahead of print).Google Scholar10. Hamadjida A, Nuara SG, Kwan C et al. Monoamine oxidase A inhibition with moclobemide enhances the anti-parkinsonian effect of L-DOPA in the MPTP-lesioned marmoset. Naunyn Schmiedebergs Arch. Pharmacol. doi:10.1007/s00210-020-01933-y (2020) (Epub ahead of print).Google Scholar11. Chiuccariello L, Cooke RG, Miler L et al. Monoamine oxidase-A occupancy by moclobemide and phenelzine: implications for the development of monoamine oxidase inhibitors. Int. J. Neuropsychopharmacol. 19(1), pyv078 (2015).Crossref, Medline, Google Scholar12. Working Group on Major Depressive Disorders. Practice Guideline for the Treatment of Patients with Major Depressive Disorder. American Psychiatric Association, Washington, DC, USA (2010).Google Scholar13. Takats A, Tarczy M, Simo M, Szombathelyi E, Bodrogi A, Karpati R. Moclobemide aurorix treatment in Parkinson's disease with depression. New Trends Clin. Pharmacol. 8(1), 260 (1994).Google Scholar14. Gimenez-Roldan S, Dobato JL, Mateo D. Treatment of depression in Parkinson's disease with moclobemide: a pilot open-label study. Parkinsonism Relat. Disord. 3(4), 219–225 (1997).Crossref, Medline, CAS, Google Scholar15. Sternic N, Kacar A, Filipovic S, Svetel M, Kostic VS. The therapeutic effect of moclobemide, a reversible selective monoamine oxidase A inhibitor, in Parkinson's disease. J. Clin. Neuropharmacol. 21(2), 93–96 (1998).Medline, CAS, Google Scholar16. Steur EN, Ballering LA. Moclobemide and selegeline in the treatment of depression in Parkinson's disease. J. Neurol. Neurosurg. Psych. 63(4), 547 (1997).Crossref, Medline, CAS, Google Scholar17. Jansen Steur EN, Ballering LA. Combined and selective monoamine oxidase inhibition in the treatment of depression in Parkinson's disease. Adv. Neurol. 80, 505–508 (1999).Medline, Google Scholar18. Korpelainen JT, Hiltunen P, Myllyla VV. Moclobemide-induced hypersexuality in patients with stroke and Parkinson's disease. Clin. Neuropharmacol. 21(4), 251–254 (1998).Medline, CAS, Google Scholar19. Nomoto M, Irifune M, Fukuzaki K, Fukuda T. Effects of bifemelane on parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the common marmoset. Neurosci. Lett. 178(1), 95–98 (1994).Crossref, Medline, CAS, Google Scholar20. Cantagrel A, Dordain G, Dostert P. [Toloxatone, parkinsonism and dopa therapy]. Therapie 41(6), 493–497 (1986).Medline, CAS, Google Scholar21. Valade D, Baron JB. [Statokinesimetric study of the effect of minaprine on tonic postural activity in akineto-hypertonic Parkinson patients]. Agressologie 24(1), 47–55 (1983).Medline, CAS, Google ScholarFiguresReferencesRelatedDetailsCited ByDetecting Monoamine Oxidase A and B Proteins: A Western Blotting Protocol and Some Practical Considerations29 September 2022 Vol. 10, No. 6 Follow us on social media for the latest updates Metrics Downloaded 145 times History Received 7 August 2020 Accepted 17 August 2020 Published online 27 August 2020 Published in print December 2020 Information© 2020 Future Medicine LtdKeywordsmoclobemidemonoamine oxidase AParkinson's diseaseparkinsonismFinancial & competing interests disclosureThe author has no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.No writing assistance was utilized in the production of this manuscript.PDF download